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Abstract
Proteins involved in mitochondrial metabolic pathways engage in functionally relevant multi-enzyme complexes. We
previously described an interaction between short-chain 3-hydroxyacyl-coenzyme A dehydrogenase (SCHAD) and
glutamate dehydrogenase (GDH) explaining the clinical phenotype of hyperinsulinism in SCHAD-deficient patients and
adding SCHAD to the list of mitochondrial proteins capable of forming functional, multi-pathway complexes. In this work,
we provide evidence of SCHAD’s involvement in additional interactions forming tissue-specific metabolic super complexes
involving both membrane-associated and matrix-dwelling enzymes and spanning multiple metabolic pathways. As an
example, in murine liver, we find SCHAD interaction with aspartate transaminase (AST) and GDH from amino acid metabolic
pathways, carbamoyl phosphate synthase I (CPS-1) from ureagenesis, other fatty acid oxidation and ketogenesis enzymes
and fructose-bisphosphate aldolase, an extra-mitochondrial enzyme of the glycolytic pathway. Most of the interactions
appear to be independent of SCHAD’s role in the penultimate step of fatty acid oxidation suggesting an organizational,
structural or non-enzymatic role for the SCHAD protein.
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Introduction
Mitochondrial metabolic pathways provide critical mechanisms
for the generation of ATP through oxidative phosphorylation, the
tricarboxylic acid cycle and fatty acid beta-oxidation, as well as for
the disposal of ammonium through ureagenesis. Previous studies
have identified functionally relevant protein-protein interactions
across these mitochondrial metabolic pathways. For example,
mitochondrial aspartate aminotransferase (AST) has been shown
to form complexes with both glutamate dehydrogenase (GDH) in
the glutamine degradation pathway and carbamoyl phosphate
synthase-1 (CPS-1), the first enzyme committed to ammonium
removal. Several groups have independently identified this
interaction of GDH with CPS-1 [1–3]. Additionally, studies have
shown that these physical interactions effect regulation of the
individual enzyme activities. Fahien and coworkers demonstrated
that CPS-1, and its cofactors ATP and Mg
++ interact synergisti-
cally to facilitate GDH activity and to facilitate the interaction
between GDH and AST [4]. This group proposed that these
enzymes react in sequence as a multienzyme cluster within the
mitochondrial matrix. There is also evidence for direct interaction
between individual components of the fatty acid oxidation
pathway and those of the respiratory chain [5–7].
More recently, a large protein complex association between
inner mitochondrial membrane-associated enzymes of fatty acid
oxidation and complexes of the respiratory chain has been
identified [8]. The physical association between the two energy-
generating pathways has long been postulated from overlapping
clinical phenotypes in genetic deficiency states [9–11] but firm
evidence for a complex formation was previously lacking. The
studies of Wang et al. [8] also demonstrated association between
some mitochondrial matrix enzymes and the fatty acid-respiratory
chain complex, including association with isovaleryl-CoA dehy-
drogenase and short-chain acyl-CoA dehydrogenase. This work
provided the first evidence implicating association between
membrane-associated complexes and mitochondrial matrix pro-
teins.
In our own studies of the mitochondrial matrix-associated fatty
acid oxidation enzyme short-chain 3-hydroxy acyl-CoA dehydro-
genase (SCHAD), we have demonstrated a novel regulatory role
and distinct physical association between SCHAD and GDH. This
interaction defined the mechanism of hyperinsulinism in children
with SCHAD deficiency [12]. This study delineated a non-
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with GDH, resulted in down regulation of GDH activity and
provided an inhibitory mechanism on insulin release by pancreatic
beta cells. In settings in which genetic defects led to an absence of a
stable SCHAD protein, this inhibition was lost resulting in
unregulated GDH activity and excessive insulin release as
described in the patients with mutations that resulted in lack of
SCHAD protein [13–15]. By contrast, SCHAD- deficient patients
who still produced normal sized protein with a physical GDH
interaction, such as those with missense mutations in the enzyme,
showed no evidence of hyperinsulinism [16].
In earlier pull down studies from murine liver using histidine-
tagged SCHAD (His-Tag SCHAD), we recognized that, in
addition to GDH, both CPS-1 and 3-hydroxy-3-methylglutaryl-
CoA lyase (HMG-CoA lyase) from the hepatic mitochondrial
ketogenesis pathway were also identified [12]. To confirm these
protein associations with the SCHAD protein and test the
hypothesis that there is a multienzyme complex involving several
metabolic pathways within the mitochondrial matrix, we per-
formed additional experiments from multiple murine tissues to
evaluate the extent and nature of the metabolic complexes present
involving SCHAD. Here, we report evidence for large, tissue-
specific metabolic complexes involving several important mito-
chondrial pathways consisting of both matrix-associated proteins
and proteins known to be associated with the inner mitochondrial
membrane and also, and surprisingly, association of SCHAD with
some proteins considered to be extra mitochondrial.
Materials and Methods
Mouse Tissues
Mouse tissues from SCHAD knockout and wild type mice were
excess tissues that had previously been snap frozen during earlier
published experiments [12]. No additional animals were sacrificed
for these present experiments.
Yeast Two Hybrid Analysis
The DupLEX-A yeast two-hybrid system (OriGene Technolo-
gies, Rockville, MD) was used to screen a human placental
LexAcDNA library (OriGene Technologies, Rockville, MD) with
human SCHAD cDNA encoding amino acids 75–119 fused to
LexA in plasmid pEG202 as bait. Fragments of this clone, similarly
fused in pEG202, are shown in Fig. 1. Expression of bait proteins
was confirmed by Western blot by using LexA antibody.
According to the protocol supplied by OriGene, bait plasmid
SCHAD 75–119 was tested for its autoactivation potential and
ability to enter the nucleus and bind LexA operators. Of <1610
6
colonies screened, 25 were positive. Plasmids recovered from
positive clones were transformed into KC8 bacteria to select
colonies containing only target plasmids. The b-galactosidase filter
assay was used to assess interaction of SCHAD with other proteins
and positives were placed on a grid to small plates, and LacZ filter
assay was performed. To confirm the association and identify the
site(s) of interaction of SCHAD and positive interactants from
initial Lac Z assay, a mating assay was performed. SCHAD and
each of the fragments in pEG202 were transformed with pSH18–
34 reporter plasmid into RFY206 cells. Proteins coded by cDNA
in pJG4.5 (target plasmid) were transformed into EGY48 cells.
PCR for bait
SCHAD bait was amplified using a human cDNA library
prepared from human liver tissue (OriGene Technologies, Rock-
ville, MD). PCR was performed using Amplitaq Gold kit (Applied
Biosystems) using the following primers, forward
59TCCTGGCAAAATCCAAAAAG39 and reverse 59ACA-
GACTTGGTGGTGGAAG39.
Protein Pulldown
Recombinant SCHAD (or polyclonal aldolase antibody) linked
to agarose beads were used for pulldown experiments from various
mouse tissue homogenates using identical conditions described for
SCHAD. Recombinant SCHAD was expressed and purified in
our laboratory using Ni-his columns (Pierce, Rockford, IL, USA).
SCHAD-protein pull down was performed using AminoLinkPlus
Immobilization Kit (Pierce, Rockford, IL, USA) following the
manufacturer’s instructions. Briefly, SCHAD was linked to
agarose beads using cyanoborohydride and excess SCHAD
protein was washed out. Bovine serum albumin (BSA, fatty acid
free, Sigma Chemical, CO, USA) was used as the control protein
and immobilized to agarose beads similar to the SCHAD protein.
Tissues were homogenized in 50 mM Tris-HCl buffer contain-
ing 0.1% Triton-X 100 and centrifuged at 3000 rpm to separate
nuclear and non disrupted tissues. Protein concentration was
determined using Lowry’s method and protein concentration was
adjusted to 1 mg/mL. Homogenates from tissues were incubated
for interactions with immobilized SCHAD, polyclonal fructose
bisphosphate aldolase antibody or BSA at 4uC overnight. Proteins
were eluted from agarose beads following the manufacturer’s
instructions and identified using mass spectrometric analysis for
the SCHAD pulldown experiments and by Western blot using
methods we have previously validated for the identification of
SCHAD [16].
Mass spectral identification and validation
Samples were lysed in SDT (4% SDS, 0.1 M Tris-HCl pH 7.6,
0.1 M DTT) and digested with trypsin using the FASP method
essentially as described [17]. After C18 StageTip cleanup, the
tryptic digests were loaded on a 20 cm675 um C-18 column
packed with 2.7 um Halo beads (Michrom Bioresources). Nano-
flow chromatography (300 nL/min) was performed at 60uC
(Phoenix S&T column header) using a 90-minute gradient of
2%–.42% acetonitrile in 0.1% formic acid. Online chromatog-
raphy was coupled to a Thermo Scientific LTQ Orbitrap using a
Phoenix S&T AutoNano spray source. A top-5 data-dependent
MS/MS method was used with MS acquisition in the Orbitrap
and MS/MS fragmentation and measurement in the linear ion
trap. All samples were analyzed with two technical replicates.
Resulting data files were processed using MaxQuant 1.0.13.13
[18], and spectra were searched with Mascot against the IPI
mouse database v. 3.52 with carbamidomethylation of cysteine as
a fixed modification and ox (M), N-term acetylation as dynamic
modifications. All data were filtered at a 1% FDR (false discovery
rate) using a decoy database and a minimum of two peptides were
required to confirm the presence of a protein.
Plasma amino acid analysis
Amino acids were measured in plasma from wild type and
knockout mice in both fasted and fed conditions by ultra-
performance liquid chromatography using an assay that has been
validated for clinical activities [19].
Results
Yeast-2 hybrid study
To identify additional protein-protein interactions with
SCHAD, we first undertook a yeast 2-hybrid screen using a
human SCHAD (AA 77–119)-LexA fusion protein as bait. This
portion of SCHAD is shown by X-ray crystallography to form a
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screening a 2-hybrid library derived from human placental cDNA
library, this screen yielded 25 positives clones which encoded 19
different proteins. Sequences were searched against the Genbank
database, and SCHAD-interacting proteins identified in these
experiments (along with their Genbank accession IDs) are listed in
Table 1. Notably, the assay identified several mitochondrial
proteins of interest including GDH, AST, and CPS- I. Six of the
positive clones encoded tumor necrosis factor receptor-associated
factor (TRAF) family proteins.
Protein Pulldown
In order to provide a second, independent approach to identify
protein-protein interactions of SCHAD, we undertook a pulldown
strategy in conjunction with protein identification by tandem mass
spectrometry. Histidine-tagged SCHAD was immobilized on
agarose beads, and interacting proteins from murine tissue extracts
were isolated using affinity chromatography in preparation for
LC-MS/MS identification. This approach allowed us to identify
conserved SCHAD interactions as well as to extend our initial
work across a variety of tissue types. In this study we analyzed
tissues from both wild-type and SCHAD knockout mice. This was
based on our earlier observation that, at least in pancreas, in the
wild type mouse, GDH was fully occupied by SCHAD due to
molar excess of SCHAD in this tissue. We determined that there
was a risk that proteins such as GDH may not be available to
pulldown in the wild type situation. Our results demonstrated that
the two murine lines demonstrated comparable pull down profiles
across most of the associations. This complementary strategy
recognized many of the same protein interactions that we had
identified using the yeast-2-hybrid assay thus providing additional
evidence that the initial proteins were true interactants with
SCHAD. Table 2 provides an abbreviated listing of many of the
important associations in different tissues. Supplementary Tables
S1,S2,S3,S4,S5 provides a full listing of all proteins identified in
association with SCHAD and the number of confirmatory
peptides for each protein.) Using the affinity chromatography
and proteomics approach, we also identified several other
mitochondrial proteins that were not identified using the yeast-2-
hybrid approach. The majority of the proteins identified following
protein pulldown were enzymes involved in cellular energy
metabolism and maintained predicted tissue specificity patterns.
This list of interacting proteins includes key regulatory enzymes in
metabolic pathways such as fatty acid oxidation, ketogenesis,
amino acid catabolism and ureagenesis. Interestingly, we also
identified association of SCHAD with some of the enzymes of
glycolysis, an extra-mitochondrial energy pathway.
In order to confirm this unexpected association of SCHAD with
non-mitochondrial cytosolic enzymes, we undertook additional
immunoprecipitation experiments directed at confirming the
association with one of the glycolytic enzymes, fructose-bispho-
sphate aldolase. Pulldown from tissue extracts derived from mice
with wild-type SCHAD were undertaken using an anti-aldolase
antibody, and Western blot analysis confirmed the copurification
of aldolase and SCHAD (Figure 1). Moreover, this analysis
demonstrated that the SCHAD species pulled down by fructose
bisphosphate aldolase was of equivalent molecular size to the
mitochondrial form of SCHAD following intramitochondrial
cleavage of the mitochondrial targeting leader peptide. Additional
Western blot experimentation using washed red blood cells, which
should not express mitochondrial proteins, did not demonstrate
Figure 1. Western blot of SCHAD following pulldown with fructose bisphosphate aldolase. Lane 1, homogenized liver SCHAD control,
Lane 2 albumin blank, Lanes 3 and 4 results from 2 separate pulldown experiments showing a normal sized mitochondrial SCHAD.
doi:10.1371/journal.pone.0035048.g001
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support for co-compartmentalization with aldolase.
Our results provide evidence that SCHAD interacts with
enzymes from a diverse variety of metabolic pathways and that
these enzymes form an interacting metabolic super-complex. The
results of our SCHAD pulldown experiments are organized by
individual metabolic pathways as well as by tissue specificity.
Carbohydrate metabolism
The SCHAD pulldown experiments showed that SCHAD
protein associated in all tissues with components of the glycolytic
pathway and, to a lesser extent, enzymes of the citric acid cycle.
The major glycolytic enzymes indentified were fructose bispho-
sphate aldolase and phosphoglycerate kinase1, and citric acid cycle
enzymes included fumarate hydratase and isocitrate dehydroge-
nase. There was also a consistent association with the proteins of
the pyruvate dehydrogenase complex responsible for the genera-
tion of acetyl-CoA to fuel the citric acid cycle. We also identified a
physical interaction of SCHAD with glycogen phosphorylase, a
non-mitochondrial enzyme that is important for the regulation of
blood glucose levels from glycogen.
Glutamate metabolism
SCHAD-interacting proteins that are involved in amino acid
metabolism include GDH, AST, responsible for the transamina-
tion of glutamate to a-ketoglutarate and glutamine synthetase
which converts glutamate to glutamine and also salvages
ammonium ions. These proteins were found to be associated with
SCHAD in liver, kidney, and brain. We did not identify GDH as
an associated protein in skeletal and cardiac muscle, and it is well
established that GDH enzyme activity is not expressed in these
tissues.
Lipid metabolism
SCHAD interacted with a variety of membrane-associated and
matrix proteins involved in fatty acid b-oxidation in all tissues types
tested. Proteins identified include both subunits of the inner
mitochondrial membrane-associated trifunctional protein, which
contains the 3-hydroxyacyl-CoA dehydrogenase responsible for
oxidationoflongchainacyl-CoA species;three chain-lengthspecific
members of the acyl CoA dehydrogenase family (very long chain
acyl-CoA dehydrogenase, medium-chain acyl-CoA dehydrogenase
and short-chain acyl-coA dehydrogenase); and 3-keto-acyl CoA
thiolase,which isresponsibleforthesubsequent and finalreactionof
fatty acid oxidation after SCHAD.ACAD10, a recently described
member of the acyl-CoA dehydrogenase family is known to be
primarily expressed in brain and liver and was only seen in these
tissues in our studies. Of particular interest, although present in the
wild-type tissue pulldown in liver, heart and brain, we did not see
association of SCHAD with the membrane associated enzymes
responsible for long-chain fatty acid oxidation in the liver and brain
from SCHAD knockout tissues. Cardiac muscle, however, did
demonstrate the association in the knock-out mouse.
Urea cycle
In liver, we identified interactions with CPS-1, argininosucci-
nate (ASA) synthase and ASA lyase, important components of
ureagenesis. As seen with carbohydrate metabolism, in addition to
mitochondrial proteins, we identified some enzymes that are
localized to the cytosolic fraction (ASA synthase and ASA lyase).
We did identify individual enzymes of the urea cycle in other
Table 1. Proteins associated with SCHAD using Yeast-2 Hybrid analysis.
Protein Accession number Organelle
2-oxoglutarate dehydrogenase E1 component NM_001003941 Mitochondria
Aldehyde dehydrogenase 3-B1 NM_000694 Mitochondria
ATP synthase subunit A NM_001001937 Mitochondria
Carbamoyl phosphate synthase 1 NM_001875 Mitochondria
Citrate synthase NM_004077 Mitochondria
Electron transfer flavoprotein-ubiquinone oxidoreductase NM_004453 Mitochondria
Glutamate dehydrogenase 1 NM_005271 Mitochondria
3-Hydroxy-3-methyl glutaryl-CoA lyase NM_000191 Mitochondria
3-hydroxy-3-methyl glutaryl-CoA synthase NM_005518 Mitochondria
Pyruvate dehydrogenase E1 component subunit alpha NM_000284 Mitochondria
Pyruvate dehydrogenase E1 component subunit beta NM_000925 Mitochondria
Pyruvate dehydrogenase protein X component NM_003477 Mitochondria
Mitochondrial trifunctional protein subunit alpha NM_000182 Mitochondria
Mitochondrial trifunctional protein subunit beta NM_0001983 Mitochondria
Fructose-bisphosphate aldolase C NM_001127617 Cytosol
Glutamine symthase NM_001033056 Cytosol
Malate dehydrogenase NM_001199111 Cytosol
Glycogen phosphorylase NM_002863 Cytosol
TRAF3 interacting protein 2 NM_001164282 Cytosol
TRAF5 interacting protein NM_001033910 Cytosol
TRA6 interacting protein NM_004620 Cytosol
doi:10.1371/journal.pone.0035048.t001
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in association with SCHAD in kidney, and arginase-2, the
mitochondrial form of arginase in brain.
Other pathways
HMG-CoA synthase and HMG-CoA lyase play a role in
mitochondrial ketogenesis and were identified in liver using both
yeast-2 hybrid and the affinity pulldown-proteomic techniques.
Succinyl-CoA: 3-ketoacid acyl transferase, an important enzyme for
ketone body utilization was identified in all tissues except the heart
muscle. One electron transfer protein (ETF-Ubiquinone oxidore-
ductase) was identified in liver using the yeast-2 hybrid assay, whilst
both ETF and ETF ubiquinoneoxidoreductase wereidentified using
pulldown-proteomictechniquesinallofthetissuesstudied.Usingthe
yeast 2 hydbrid technique, we identified three related TNF receptor
associated factor family of proteins: TRAF3, 5 and 6. We also
identified association of SCHAD with several oxidative phophoryla-
tion enzymes in our study, with the majority of them identified in
brain. These enzymes include NADH-cytochrome oxidoreductase,
cytochrome bc1 complex, succinate dehydrogenase, cytochrome
oxidase, and members of the ATP synthase complex.
Amino acid profiles
Amino acid profiles and blood ammonia levels were obtained
from wild type and SCHAD knockout mice in both fasted and fed
conditions. A total of 5 animals in each subgroup were studied. We
did not detect significant changes in any circulating amino acid
level between the wild type or knockout in either fasting or fed
status. In particular we did not see evidence of altered ureagenesis
through changes in the levels of ammonia, glutamine, ornithine,
citrulline or arginine, or alterations in the levels of glutamate or
aspartate.
Discussion
In this study, we have identified protein-protein interactions
between SCHAD, the penultimate enzyme of mitochondrial fatty
acid b-oxidation and multiple other mitochondrial and some non-
mitochondrial metabolic proteins. We initially examined SCHAD
interactions using a yeast-2 hybrid system and identified 21
interacting proteins as candidates for a metabolic super-complex.
Next, we used immobilized SCHAD on agarose beads coupled
with mass spectrometric proteomic analysis to confirm our initial
yeast-2-hybrid findings. The process of pulldown with mass-
spectrometric identification has greater inherent sensitivity for
detecting proteins and has the advantage of allowing us to rapidly
test whether different interaction sets are identified within different
tissues. Our results from these affinity chromatography protein
pull down experiments coupled with mass-spectrometric identifi-
cation provided valuable verification of the proteins that were
identified using the yeast-2 hybrid technique. Using these
Table 2. Proteins found in association with SCHAD by pulldown*.
Pathway Liver Muscle Heart Kidney Brain
Fatty Acid Oxidation
carnitine palmitoyl transferase 2 Yes No No Yes Yes
very long chain acyl-CoA dehydrogenase Yes** No Yes No Yes**
trifunctional enzyme alpha Yes** No Yes No Yes**
trifunctional enzyme beta Yes** No Yes No Yes**
medium chain acylCoA dehydrogenase Yes yes Yes No Yes
long chain acyl-CoA dehydrogenase Yes No Yes No Yes
3-ketoacyl-coA thiolase No No Yes No No
ACAD 10 Yes No No No Yes
Glutamate/amino acid/urea cycle
glutamate dehydrogenase Yes No No Yes Yes
carbamoyl phosphate synthase 1 Yes No No No No
argininosuccinate synthase Yes No No Yes No
argininosuccinate lyase Yes No No Yes No
glutamine synthase Yes Yes Yes Yes Yes
aspartate aminotransferase Yes Yes No Yes Yes
Ketogenesis/ketone utilization
succinyl-CoA: 3-ketoacid acyl transferase Yes Yes No Yes Yes
hydroxymethyl-CoA synthase Yes No No No No
hydroxymethyl-coA lyase Yes No No No No
Oxidative phosphorylation/TCA cycle
NADH dehydrogenase flavoprotein 2 Yes Yes No Yes Yes
NADH dehydrogenase iron-sulfurprotein2 Yes No No No No
Glycolysis
fructose bis phosphate aldolase Yes Yes Yes Yes Yes
*The full proteomic data including numbers of confirming peptides in both wild type and SCHAD knockout mice is provided in the supporting material.
**These long-chain inner mitochondrial-associated enzymes were only seen in the wild-type mouse in liver and brain.
doi:10.1371/journal.pone.0035048.t002
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published protein-protein interaction between SCHAD and
several other mitochondrial proteins in liver including GDH,
CPS1 and HMG-CoA lyase; further, we have revealed new
interactions that have not previously been recognized and that
together provide evidence for the possible existence of a cellular
‘‘metabolic super complex’’ integrating multiple metabolic path-
ways.
The identification of these novel interactions underscore a role
for the SCHAD protein as an essential component not only of
metabolic pathways within the mitochondria but also with those
that are not currently regarded as being mitochondrial. Given the
surprising nature of this result, we performed reciprocal co-
immunoprecipitation to confirm an interaction between SCHAD
and fructose bisphosphate aldolase. These experiments appear to
confirm a direct or indirect physical interaction between SCHAD
and a glycolytic enzyme known to be localized in another
intracellular compartment.
Our previous observations of the role of SCHAD in non-
enzymatically regulating the function of GDH suggest the
possibility that SCHAD might regulate or modulate the function
of other critical enzymes through protein-protein interactions [12].
Hardy et al., using a functional genomics approach, observed that
SCHAD promotes basal insulin secretion independent of KATP
channels [20]. Several similar studies in which SCHAD was
knocked down using shRNA or RNAi techniques in INS832/13 b-
cells showed increased glucose stimulated secretion of insulin
[21,22].The increase in the insulin secretion in response to various
metabolites such as L-carnitine and 3-hydroxybutyrate was also
affected [22]. In our earlier study we were able to demonstrate that
GDH activity was up regulated in the absence of SCHAD in a
fashion similar to that seen in hyperinsulinism due to gain-of-
function mutations in GDH [23], and this provides a paradigm
that may be relevant across additional SCHAD protein-protein
interactions. Kapoor et al. described novel SCHAD mutations in a
patient with severe dietary protein intolerance [24]. We have
analyzed plasma amino acids in the SCHAD-deficient mouse to
see if the interactions with proteins that are responsible for amino
acid and urea cycle pathways provide clues to other regulatory
roles of SCHAD in associated pathways or to the protein
sensitivity. We could not find any obvious changes in pathways
involving ammonia removal through the measurement of urea
cycle intermediates or glutamine or to known post-prandial
elevations including leucine and the other branched-chain amino
acids. It remains possible that SCHAD does not have a direct
regulatory role in this pathway but that other components of the
complex do. Unlike patients with gain of function mutations in the
GDH gene, who demonstrate profound hyperammonemia in
association with hyperinsulinemic hypoglycemia [23], patients and
the knock out mouse with SCHAD deficiency do not demonstrate
hyperammonemia. This suggests that the hyperammonemia seen
with GDH mutations may result from an adverse interaction with
other protein(s) within the complex.
In our earlier studies on SCHAD-GDH interaction in
pancreatic islet cells we observed that the association between
these two proteins in the wild-type mouse was complete and that in
this scenario GDH was blocked. We were only able to confirm
pancreatic islet association in the SCHAD knockout mouse.
Subsequently, we performed the current study using tissues from
both wild type and SCHAD knockout mice for comparison. The
majority of proteins identified by mass spectrometry had similar
profiles and recoveries, based on peptide sequence numbers, from
both wild type and knockout mice. The major exception that we
observed was that in the knock out mouse a number of enzymes of
mitochondrial fatty acid oxidation were no longer seen to be
associated in some tissues. This was particularly apparent for the
trifunctional enzyme subunit beta and very long-chain specific
acyl-CoA dehydrogenase in brain and liver and also short-chain
specific acyl-CoA dehydrogenase in liver and medium-chain
specific acyl-CoA dehydrogenase in skeletal muscle. However, all
of these enzymes were identified as equal components in both wild
type and SCHAD knockout cardiac muscle. Taken together, this
evidence suggests that the loss of SCHAD does result in loss of
both membrane associated and matrix associated members of the
fatty acid oxidation pathway in some tissues due to structural
changes in the super-complex. This loss of structure is not seen in
cardiac muscle suggesting a more stable complex in heart which is
a tissue that has an obligate need for fatty acid oxidation as an
energy source. Also, cardiac muscle was the only tissue that did not
show association with succinyl-CoA: 3-ketoacid acyl transferase,
an important enzyme in ketone body utilization as an energy
source, indicating that ketones may not be important fuels for
heart energetics.
We also identified associations between SCHAD and several
urea cycle enzymes, including the extra-mitochondrial ASA
synthase and ASA lyase in liver. We speculate that the functional
significance of the association between the SCHAD and urea cycle
enzymes may be related to the requirement of N-acetylglutamate
(NAG) as an activator of the first enzymatic step of ureagenesis,
which is catalyzed by CPS-1. The end product of fatty acid
oxidation through the thiolase step is acetyl-CoA which in addition
to glutamate is essential for activation of CPS-1. Hardy et al. [20]
demonstrated that inhibition of ASA synthase 1 expression by
RNAi techniques resulted in decreased secretion of insulin. This
suggests that ASA synthase is a potential activator of insulin
secretion, perhaps through its interaction with the known down-
regulator of GDH activity, SCHAD. This also provides further
evidence that is consistent with our proposal of a metabolic super-
complex. Of note, the rate-limiting enzyme in ureagenesis, CPS-1,
was associated with SCHAD only in the liver. Expression of CPS-1
is limited to the liver and kidney and the expectation is that
interaction should only occur in a tissue-specific manner. Although
more studies are necessary to confirm the physiological relevance
of these associations, it is clear that SCHAD has a potential role as
a modulator in the urea cycle. Additionally, in liver (but not other
tissues) we identified an association with the two enzymes of ketone
body formation, HMG-CoA synthase and HMG-CoA lyase. We
would not expect to see these proteins in other tissues where
ketone bodies are not synthesized.
Our pull down studies revealed an interaction between SCHAD
and several components components of the mitochondrial
oxidative phosphorylation system. Interactions with several
functional components of the OX/PHOS system, including
NADH-ubiquinone oxidoreductase, succinate dehydrogenase,
cytochrome bc1 complex, cytochrome c oxidase and others, were
identified. In contrast, the relative lack of OX/PHOS structural
components identified suggests that interactions of SCHAD may
be more specific to catalytic components of this pathway. This is in
keeping with the role of SCHAD and also the trifunctional protein
as NADH-generating enzymes demonstrating a logical physical
association with the regeneration of NAD through the respiratory
chain.
Our yeast-2-hybrid studies have identified physical interactions
between SCHAD and some of the TRAF family of proteins,
specifically TRAF3, 5 and 6. Studies of the TRAF6 knockout
mouse model have shown a defect in mitochondrial fatty acid
oxidation as well as in AMP activated kinase activation in CD8
+ T
cells [25]. These results suggest that TRAF family proteins may
Convergence of Multiple Metabolic Pathways
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pathways both within and outside of the mitochondrion.
A model of how SCHAD and its associated proteins link the
metabolic pathways in the mitochondria is shown in Figure 2.
Several of the pathways that have been shown to associate are
centered on glutamate metabolism. The primary function of
SCHAD is the conversion of medium and short-chain L-3-
hydroxyacyl–CoA’s to their respective 3-ketoacyl-CoA’s. Based on
the pathway components that our study identified results we have
depicted SCHAD interactions with enzymatic mediators of
ureagenesis, ketogenesis, oxidative phosphorylation, the citric acid
cycle and transamination in addition to its known enzymatic role
in fatty acid oxidation. HMG CoA synthase, CPS1, and GDH are
regulatory components of their respective pathways. Wang et al.,
[8] demonstrated the association of mitochondrial fatty acid
oxidation enzymes and oxidative phosphorylation complexes using
blue native gel electrophoresis techniques. This was the first study
that established a metabolic complex between mitochondrial
membrane and matrix protein associations. In our present study,
we have identified a similar complex of both matrix and
membrane-associated proteins using SCHAD, which is a mito-
chondrial matrix protein.
Hardy et al, [20] utilized a functional genomics approach to
look at possible interactions of SCHAD and identified several of
the proteins that we report. Our previous studies and those of
others provide support by other studies from and provide support
that the physical interactions of SCHAD, separate and apart from
its primary enzymatic role, may be important in modulating
multiple pathways of metabolism [8,20,22].
In conclusion, we have demonstrated a physical association
between SCHAD and important components of other key
metabolic pathways. Most of the interactions are with enzymes
in mitochondrial pathways and most of the interactions appear to
be independent of the primary role of SCHAD as an enzyme
responsible for the penultimate step of fatty acid oxidation. These
interactions would define a metabolic super-complex where
multiple metabolic pathways converge. Unexpectedly, we also
identified a number of non-mitochondrial protein reactions on
classical pathways that are related to those of the mitochondria
including energy metabolism through glycolysis and ureagenesis
through extra-mitochondrial urea cycle proteins. Pulldown using
fructose bisphosphate aldolase confirmed these associations. It is
well known that glycolytic enzymes associate with mitochondria
[26] but direct associations so far have been limited to membrane
constituents including H
+ ATPases suggesting a role in regulating
mitochondrial membrane potential [27]. A recent study by Genda
and coworkers identified co-compartmentalization of an astroglial
glutamate transporter with glycolytic enzymes and mitochondria
using methods that are similar to ours and providing additional
evidence to support the association of glycolysis and mitochondrial
metabolism [28]. Association of glycolytic enzymes with mito-
chondrial matrix proteins has not previously been described but
we consider that our observation that this is so using pulldown
with both proteins suggests that this is a real phenomenon. We
were unable to demonstrate the presence of SCHAD protein
outside of the mitochondria as demonstrated by our western blot
analysis of red blood cell preparations. A possible linkage
mechanism between the matrix proteins and those of glycolysis
may come through the mitochondrial membrane associated
Figure 2. Interactions of several metabolic pathways represented as components of the proposed mitochondrial matrix super
complex. The pathways include fatty acid oxidation, ketogenesis, glutamate transamination, ureagenesis and the TCA cycle.
doi:10.1371/journal.pone.0035048.g002
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it to be highly unlikely that the enzymatic activity of SCHAD is
required as part of these observed interactions, we suggest
additional structural and potential regulatory roles for SCHAD.
Potential regulatory roles between the associated proteins form the
basis of our ongoing studies and the full nature of this association
remains to be elucidated.
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